Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.

ABSTRACT:

Background

The outcomes of patients diagnosed with head and neck squamous cell carcinoma (HNSCC) who are not candidates for local salvage therapy and of those diagnosed with recurrent or metastatic disease are dismal. A relatively new systemic therapy option that emerged in recent years in the treatment of advanced HNSCC is immunotherapy using immune checkpoint inhibitors (ICIs). The safety profile and anti-tumor activity of these agents demonstrated in early phase clinical trials paved the way to the initiation of several promising phase-3 trials in the field.

Aim

To evaluate the evidence on the effectiveness of ICIs in HNSCC, based on published phase-3 clinical trials.

Methods

We searched PubMed, Cochrane Library, Embase, and Scopus to identify published literature

SUBMITTER: Poulose JV 

PROVIDER: S-EPMC9153072 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature